PHI with Primary biliary cholangitis (PBC)
How does this condition affect your private health insurance?
Primary Biliary Cholangitis (PBC) is a chronic autoimmune liver disease characterized by the gradual destruction of small bile ducts within the liver. This progressive damage impairs bile flow, leading to a build-up of toxic substances. Over time, this can cause inflammation, scarring (fibrosis), and eventually cirrhosis and liver failure. Symptoms often include fatigue and pruritus (itching), though many are asymptomatic at diagnosis, triggered by abnormal liver function tests. While there is no cure, treatment, primarily with ursodeoxycholic acid (UDCA), aims to slow disease progression and manage symptoms, preserving liver function for as long as possible.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Several months to years before symptomatic presentation or diagnosis due to insidious onset.
Duration of Illness (Lifetime)
Chronic, lifelong condition.
Cost of Treatment (Initial)
Hundreds to several thousands of USD for initial diagnosis and medication setup, depending on tests and region.
Cost of Treatment (Lifetime)
Tens of thousands to hundreds of thousands of USD over a lifetime, potentially millions if liver transplant is required.
Mortality Rate
Significant if untreated or progresses to liver failure without transplant; lower with early diagnosis and consistent treatment.
Risk of Secondary Damages
Very high, including cirrhosis, portal hypertension, osteopenia/osteoporosis, malabsorption, severe fatigue, pruritus, and increased risk of hepatocellular carcinoma.
Probability of Full Recovery
Extremely low; no cure, treatment aims to manage and slow progression rather than achieve complete recovery.
Underlying Disease Risk
Moderate to high (e.g., Sjögren's syndrome, autoimmune thyroid disease, rheumatoid arthritis, celiac disease).